BioMerieux SA

BIM

Company Profile

  • Business description

    BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l'Etoile, France.

  • Contact

    Marcy l’Etoile
    Lyon69280
    FRA

    T: +33 478872000

    E: [email protected]

    http://www.biomerieux.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2025

    Employees

    14,754

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.7048.800.56%
CAC 407,929.9651.500.65%
DAX 4024,590.0040.440.16%
Dow JONES (US)44,458.30217.540.49%
FTSE 1008,968.71101.691.15%
HKSE24,028.37136.050.57%
NASDAQ20,611.34192.870.94%
Nikkei 22539,646.36174.92-0.44%
NZX 50 Index12,760.208.41-0.07%
S&P 5006,263.2637.740.61%
S&P/ASX 2008,589.2050.600.59%
SSE Composite Index3,509.6816.630.48%

Market Movers